Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway

BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Koleini, Navid, Nickel, Barbara E., Wang, Jie, Roveimiab, Zeinab, Fandrich, Robert R., Kirshenbaum, Lorrie A., Cattini, Peter A., Kardami, Elissavet
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675643/
https://ncbi.nlm.nih.gov/pubmed/29152091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20558
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars